Natco Pharma NATCOPHARM
Niche US generics through Para IV challenges and partners (gRevlimid with Teva), India oncology, agrochemicals and an Africa platform
Mapped in 1 theme: Pharmaceuticals.
Where Natco Pharma sits in the supply chain
Natco Pharma appears in 1 supply-chain layer in one theme, Pharmaceuticals.
Pharmaceuticals › Generics (US & export)
Direct supplierOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 3,999 | 4,430 | 4,078 |
| Net profit | 1,388 | 1,883 | 1,418 |
Latest-year revenue ₹4,078 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Proven Para IV/first-to-file skill - gRevlimid earned outsized profits FY24-FY25
- Net-cash balance sheet; now 49% of South Africa's Adcock Ingram (Jul 2026)
- First wave of generic semaglutide in India at ~₹1,290 a month
Risks
- gRevlimid volume-limited deal ended Jan 2026 - FY26 profit fell 25% and FY27 resets lower
- Lumpy earnings tied to a few launches and litigation outcomes
- Agrochemical and Africa diversification are unproven at scale
Common questions
What does Natco Pharma do?
Niche US generics through Para IV challenges and partners (gRevlimid with Teva), India oncology, agrochemicals and an Africa platform.
Where does Natco Pharma sit in the supply chain?
Natco Pharma (NSE: NATCOPHARM) is mapped in 1 supply-chain layer: Generics (US & export) (Pharmaceuticals).
Who are Natco Pharma's peers?
In the Generics (US & export) layer of Pharmaceuticals: Dr Reddy's Laboratories, Aurobindo Pharma, Lupin, Zydus Lifesciences, Cipla, Sun Pharmaceutical Industries and 6 more.
What is Natco Pharma's market cap and valuation?
As of 30 Oct 2026: market cap ₹15,344 Cr, P/E 13.4x, ROCE 17.4%, ROE 17.1%, dividend yield 0.64%.